Patents Issued in April 1, 2004
  • Publication number: 20040063690
    Abstract: The present invention relates to compounds of formula I: 1
    Type: Application
    Filed: October 1, 2003
    Publication date: April 1, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GmBH
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Publication number: 20040063691
    Abstract: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
    Type: Application
    Filed: September 24, 2002
    Publication date: April 1, 2004
    Inventors: Roger A. Smith, Stephen J. O'Connor, Stephan-Nicholas Wirtz, Wai C. Wong, Soongyu Choi, Harold C.E. Kluender, Ning Su, Gan Wang, Furahi Achebe, Shihong Ying
  • Publication number: 20040063692
    Abstract: This invention relates to extended dosing regimens for the selective estrogen receptor modulator bazedoxefine (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1 H-indol-5-ol).
    Type: Application
    Filed: June 13, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Barry Samuel Komm, Simon Nicholas Jenkins, James Charles Ermer, Mark Andrew Collins, Geraldine Marie Ferron, Pol Boudes, Wendy Ann Dulin
  • Publication number: 20040063693
    Abstract: Compounds of the general formula (I): 1
    Type: Application
    Filed: July 17, 2003
    Publication date: April 1, 2004
    Inventors: Magnus Cernerud, Helena Lundstrom, Bjorn M. Nilsson, Markus Thor
  • Publication number: 20040063694
    Abstract: The present invention relates to the compound 2-ethyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][l,5]benzodiazepine and its use as is or in substantially pure form in the treatment of CNS disorders including schizophrenia and bipolar disorder. The compound is prepared by reacting a substituted thiophene compound with 2-fluoronitrobenzene to form, after ring closure and reaction with N-methylpiperazine, the title compound. The compound is then purified to substantially pure form and is useful as an antipsychotic. The compound may also be combined with other active ingredients including HMG CoA reductase inhibitors such as lovastatin or simvastatin and/or antidepressants such as fluxoetine or other SSRIs to form medically useful combination products useful in treating psychotic conditions and depression while also preventing any rise beyond the normal range of cholesterol levels in any subset of patients that might develop such a condition.
    Type: Application
    Filed: June 3, 2003
    Publication date: April 1, 2004
    Inventor: Monte R. Browder
  • Publication number: 20040063695
    Abstract: The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound.
    Type: Application
    Filed: September 30, 2002
    Publication date: April 1, 2004
    Inventors: Alan Verkman, Tonghui Ma
  • Publication number: 20040063696
    Abstract: 1 wherein: represents a single or double bond, R1 represents a hydrogen atom or a hydroxy, alkoxy, acyloxy, alkylsulphonyloxy, arylsulphonyloxy or arylalkoxy group, R2 represents a hydrogen atom or an alkyl group, R3 and R4, which may be identical or different, each represent a hydrogen atom, a halogen atom or an alkyl, hydroxy or alkoxy group, Ak represents an alkylene chain, R5, R6 and R7, which may be identical or different, each represent an alkyl group, or R5, R6 and R7, taken together with the nitrogen atom carrying them, form a saturated or unsaturated nitrogen-containing heterocycle,
    Type: Application
    Filed: June 20, 2003
    Publication date: April 1, 2004
    Inventors: Jean-Claude Madelmont, Isabelle Giraud, Aurelien Vidal, Emmanuelle Mounetou, Maryse Rapp, Jean-Claude Maurizis, Pierre Renard, Daniel-Henri Caignard, Jean-Guy Bizot-Espiard
  • Publication number: 20040063697
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a vaso-occlusive event. More particularly, the invention provides a combination therapy for the treatment or prevention of a vaso-occlusive event comprising the administration to a subject of a thrombolytic agent in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: June 30, 2003
    Publication date: April 1, 2004
    Inventor: Peter C. Isakson
  • Publication number: 20040063698
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventor: Thomas P. Maduskuie
  • Publication number: 20040063699
    Abstract: A novel GPR14 antagonist. The GPR14 antagonist comprises a compound represented by the formula (I) or a salt thereof wherein Ar represents optionally substituted aryl; X represents a spacer; n is an integer of 1 to 10; R represents an optionally substituted hydrocarbon group, etc., provided that R may be bonded to Ar, etc. to form a ring; and Y represents optionally substituted amino, etc.
    Type: Application
    Filed: January 2, 2003
    Publication date: April 1, 2004
    Inventors: Naoki Tarui, Takashi Santo, Hiroyuki Watanabe, Kazuyoshi Aso, Yuji Ishihara
  • Publication number: 20040063700
    Abstract: 1
    Type: Application
    Filed: July 8, 2003
    Publication date: April 1, 2004
    Inventors: Peter T.W. Cheng, Sean Chen, Pratik Devasthale, Charles Z. Ding, Timothy F. Herpin, Shung Wu, Hao Zhang, Wei Wang, Xiang-Yang Ye
  • Publication number: 20040063701
    Abstract: The present invention relates to a novel serotonin antagonist and an anti-platelet agent, more particularly, a serotonin antagonist and an anti-platelet agent which potently and specifically inhibit the serotonin 2 receptor with low adverse side effect.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 1, 2004
    Applicant: AJINOMOTO CO., INC
    Inventors: Shingo Makino, Harumi Arisaka, Hiroshi Yamamoto, Masataka Shoji, Ryota Yoshimoto
  • Publication number: 20040063702
    Abstract: A method for treating a living body afflicted with a cancer selected from lung and ovarian carcinoma, comprising the step of administering to the living animal body an amount of a compound selected from those of formula (I): 1
    Type: Application
    Filed: July 26, 2003
    Publication date: April 1, 2004
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Michel Koch, Francois Tillequin, Sylvie Michel, Elisabeth Seguin, Abdelhakim El Omri, John Hickman, Alain Pierre, Bruno Pfeiffer, Pierre Renard
  • Publication number: 20040063703
    Abstract: The invention relates to synergistic mixtures comprising one or more sodium ion channel effectors and the compound (Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazblidin-2-ylidenecyanamide or the compound (E)-1-(2-chloro-1,3-thiazol-5 -ylmethyl)-3-methyl-2-nitroguanidine or the compound 1-[(6-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidineimine and the use of these mixtures for controlling animal pests.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 1, 2004
    Inventors: Thomas Bretschneider, Rainer Fuchs, Wolfram Andersch, Ulrich Ebbinghaus-Kintscher, Christoph Erdelen
  • Publication number: 20040063704
    Abstract: The present invention relates to novel compounds of formula (1) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6-alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsullonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, arylC1-6alkyl, arylC1-6alkanoyl, a group R3OCO(CH2)s, R3CON(R4)(CH2)s, R3R4NCO(
    Type: Application
    Filed: October 16, 2003
    Publication date: April 1, 2004
    Inventors: Christopher Norbert Johnson, Harshad Kantilal Rami, Geoffrey Stemp, Kevin Thewlis, Mervyn Thompson, Antonio Keuok Keong Vong
  • Publication number: 20040063705
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Application
    Filed: August 21, 2002
    Publication date: April 1, 2004
    Inventors: Jean-Christophe Harmange, Shon Booker, John L. Buchanan, Stuart Chaffee, Perry M. Novak, Simon Van Der Plas, Xiaotian Zhu
  • Publication number: 20040063706
    Abstract: A process for the preparation of a 4,4′-bistriazinylamino-stilbene-2,2′-disulphonic acid compound of formula (I) in which, independently, each R1 represents —NH2, —NH(C1-c10alkyl), —N(C1-C10alkyl)2, —NH(C2-C4hydroxyalkyl), —NH(C2-C4hydroxyalkyl)2, —N(C1-C10alkyl)(C2-C4hydroxyalalkyl), —NH(C1-C4alkoxy-C2-C4hydroxyalkyl), —N(C1-C4alkoxy-C2-C6hydroxyalkyl)2, —N(C1-C4alkoxy-C2-C4hydroxyalkyl)(C1-C10alkyl), —N(C1-C4alkoxy-C2C4hydroxyalkyl)(C2-C4hydroxyalkyl), —NH(C1-C4alkoxy-C1-C4alkoxy-C1-C4-alkyl), —N(C1-C4alkoxy-C1-C4alkoxy-C1-C4-alkyl)2, —N(C1-C4alkoxy-C1-C4alkoxy-C1-C4alkyl)(C1-C6alkyl), —N(C1-C6alkoxy-C1-C4alkoxy-C2-C4alkyl)(C2-C4hydroxyalkyl)-NH(C5-C7cycloalkyl), —N(C5-C7cycloalkyl)2, —NH(C6-C10aryl), NH(C7-C13aralkyl) or a morpholino, piperidino or pyrrolidino residue; M represents H, Na, Li, K, Ca, Mg, ammonium, or ammonium that is mono-, di-, tri- or tetrasubstituted by C1C4alkyl, C2-C4hydroxyalkyl
    Type: Application
    Filed: July 7, 2003
    Publication date: April 1, 2004
    Inventors: Georges Metzger, Dieter Reinehr, Hanspeter Sauter, Helena Dbaly
  • Publication number: 20040063707
    Abstract: The present invention provides compounds of formula I, 1
    Type: Application
    Filed: July 18, 2003
    Publication date: April 1, 2004
    Inventors: Rajeev S. Bhide, Rejean Ruel, Carl Thibault, Alexandre L'Heureux
  • Publication number: 20040063708
    Abstract: The present invention provides compounds of formula I, 1
    Type: Application
    Filed: August 4, 2003
    Publication date: April 1, 2004
    Inventors: Rajeev S. Bhide, Robert M. Borzilleri
  • Publication number: 20040063709
    Abstract: Disclosed compounds of the formula (I) 1
    Type: Application
    Filed: January 2, 2003
    Publication date: April 1, 2004
    Applicant: SCHERING CORPORATION
    Inventors: Arthur G. Taveras, Michael Dwyer, Jianping Chao, John J. Baldwin, J. Robert Merritt, Ge Li, Jianhua Chao, Younong Yu
  • Publication number: 20040063710
    Abstract: The invention relates to an ophthalmic agent comprising, as an active ingredient, a compound having a cardiotonic action including a phenyl pyridazinone derivative or salt thereof, or a hydrate thereof or solvate thereof as a typical example. Specifically, the invention relates to a preventative and/or therapeutic agent for optic nerve diseases or retinal diseases.
    Type: Application
    Filed: October 16, 2003
    Publication date: April 1, 2004
    Inventors: Tomiya Mano, Shunji Sogo, Erie Inoue
  • Publication number: 20040063711
    Abstract: Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment of erectile dysfunction.
    Type: Application
    Filed: October 10, 2003
    Publication date: April 1, 2004
    Inventors: Jyrki Lilleberg, Lasse Lehtonen, Pertti Pentikainen
  • Publication number: 20040063712
    Abstract: Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
    Type: Application
    Filed: March 25, 2003
    Publication date: April 1, 2004
    Inventors: Mark Salvati, Stephanie A. Barbosa, Zhong Chen, John T. Hunt
  • Publication number: 20040063713
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: May 23, 2003
    Publication date: April 1, 2004
    Inventors: Marlon D. Cowart, Steven P. Latshaw, Sherry L. Nelson, Andrew O. Stewart
  • Publication number: 20040063714
    Abstract: A class of substituted 1,2,4-triazolo[4,3b]pyridazine derivatives, possessing a fluoro-substituted phenyl ring at the 3-position and a heteroaryl-methoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: June 17, 2003
    Publication date: April 1, 2004
    Inventors: William Robert Carling, Jose Luis Castro Pineiro, Ian James Collins, Alexander Richard Guiblin, Timothy Harrison, Andrew Madin, Kevin William Moore, Michael Geoffrey Russell, Gayle Scott, Leslie Joseph Street
  • Publication number: 20040063715
    Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: September 19, 2003
    Publication date: April 1, 2004
    Applicant: SCHERING CORPORATION
    Inventors: Kamil Paruch, Timothy J. Guzi, Michael P. Dwyer, Ronald J. Doll, Viyyoor M. Girijavallabhan, Alan Mallams
  • Publication number: 20040063716
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action.
    Type: Application
    Filed: June 25, 2003
    Publication date: April 1, 2004
    Inventors: Hidemitsu Nishida, Takafumi Mukaihira
  • Publication number: 20040063717
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Application
    Filed: May 21, 2003
    Publication date: April 1, 2004
    Inventors: Andrew Wolff, Markus Jerling
  • Publication number: 20040063718
    Abstract: The invention features a method of delivering a drug to a diseased cell by linking the drug to a rifamycin derivative, compositions that include drug-rifamycin conjugates of the invention, and methods for treating disease using those compositions.
    Type: Application
    Filed: November 21, 2002
    Publication date: April 1, 2004
    Inventors: Arthur F. Michaelis, Hawkins V. Maulding, Chalom Sayada, Congxiang Zha
  • Publication number: 20040063719
    Abstract: The present invention provides a method for a more efficacious treatment of a vascular condition through the administration of a therapeutically effective amount of a combination of an anti-pressor agent, an endothelin antagonist, and a sex hormone for repetitive cycles of on/off-treatment. In one embodiment, the invention provides a method for the prevention of tolerance induced by an anti-pressor agent via the inclusion of an endothelin antagonist in a combination therapy approach to remodel vascular structure and treat vascular conditions associated with a male or female sexual dysfunction, atherosclerosis, renal failure, hypertension, congestive heart failure, diabetic nephropathy, and diabetic neuropathy.
    Type: Application
    Filed: May 2, 2003
    Publication date: April 1, 2004
    Applicants: Queen's University at Kingston, Callegy Pharmaceuticals, Inc.
    Inventors: Michael A. Adams, Taben M. Hale, Jeremy P.W. Heaton
  • Publication number: 20040063720
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Publication number: 20040063721
    Abstract: The present invention relates to a method for treating thermoregulatory disorders by administering compounds and compositions of compounds which by modulating 5HT levels activate the 5HT2a receptor. The invention also relates to therapy using 5HT1a antagonists and SRIs in combination and pharmaceutical compositions and products containing it. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: August 14, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor, Terrance Andree
  • Publication number: 20040063722
    Abstract: A pharmaceutical composition suitable for topical application comprising ketoconazole in a solutio9n which comprises: (i) 13 to 50 wt % water; (ii) 45 to 85 wt % of an alcohol having a boiling point of less than 100° C.; and (iii) 2 to 30 wt % fo a non-volatile, water miscible, non-ionic surface active agent; the ketoconazole being present in an amount of 0.5 to 3 st % relative to components (i), (ii) and (iii).
    Type: Application
    Filed: February 5, 2003
    Publication date: April 1, 2004
    Inventors: Martin Whitefield, Andrew James Dixon, Susan Colette Temple
  • Publication number: 20040063723
    Abstract: The present invention relates to a process for the preparation of(3-cyano-1H-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone and salts thereof, characterised in that an indole ester of the formula II in which R is as defined in Claim 1, is converter into 3-cyano-1H-indole-7-carboxylic acid via steps (1) to (4) according to Claim 1, and this is reacted with 1-[2-(4-fluorophenyl)ethyl]piperazine of salts thereof to give the product.
    Type: Application
    Filed: July 23, 2003
    Publication date: April 1, 2004
    Inventors: Helene Crassier, Uwe Eckert, Henning Bottcher, Andreas Bathe, Steffen Emmert
  • Publication number: 20040063724
    Abstract: The present invention provides a compound of the formula: 1
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Roche Palo Alto LLC
    Inventors: Ann Marie Madera, Robert James Weikert
  • Publication number: 20040063725
    Abstract: The present invention relates to novel N-(phenylsulphonyl)glycyl-glycine compounds, which are defined by formula I and the description, as well as their method of preparation and their use in therapeutics 1
    Type: Application
    Filed: June 20, 2003
    Publication date: April 1, 2004
    Inventors: Martine Barth, Michel Bondoux, Christophe Matt, Pierre Dodey, Jean-Michel Luccarini, Jean-Luc Paquet, Didier Pruneau
  • Publication number: 20040063726
    Abstract: A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.
    Type: Application
    Filed: August 9, 2003
    Publication date: April 1, 2004
    Inventor: Linda D Artman
  • Publication number: 20040063727
    Abstract: The present invention is directed to compounds useful in inhibiting cellular proliferation. Processes of preparing such compounds are also disclosed.
    Type: Application
    Filed: August 13, 2003
    Publication date: April 1, 2004
    Inventor: Michael Peter Trova
  • Publication number: 20040063728
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Applicant: Wyeth
    Inventors: Adam M. Gilbert, Gary P. Stack
  • Publication number: 20040063729
    Abstract: The invention relates to novel triazolopyrimidines of the formula 1
    Type: Application
    Filed: October 9, 2003
    Publication date: April 1, 2004
    Inventors: Yoshinori Kitagawa, Haruko Sawada, Yutaka Kuchii
  • Publication number: 20040063730
    Abstract: The invention relates to a pharmaceutical preparation containing at least one compound of formula (I), wherein R1, R2, R3, R4 and X have the meanings as cited in claim No. 1, and to their physiologically safe salts and/or solvates, and containing; a) at least one antithrombotic agent or; b) at least one calcium antagonist or; c) at least on prostaglandin or prostaglandin derivative for producing a medicament used for treating angina, hypertension, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, right ventricular failure, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, cerebrovascular accident, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver, and for treating female sexual dysfunctions.
    Type: Application
    Filed: June 19, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann
  • Publication number: 20040063731
    Abstract: Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling
  • Publication number: 20040063732
    Abstract: The use of purine derivatives of formula (I): 1
    Type: Application
    Filed: June 26, 2003
    Publication date: April 1, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Florence Bordon-Pallier, Jean-Luc Haesslein
  • Publication number: 20040063733
    Abstract: The invention concerns quinazoline derivatives of Formula I 1
    Type: Application
    Filed: October 22, 2003
    Publication date: April 1, 2004
    Inventors: Christine Marie Paul Lambert, Patrick Ple
  • Publication number: 20040063734
    Abstract: The present invention relates to quinazolinone compounds of formula (I): 1
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventor: Jeffrey Corbett
  • Publication number: 20040063735
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: May 27, 2003
    Publication date: April 1, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, Shikha Vig
  • Publication number: 20040063736
    Abstract: The subject of the present invention is a new combination of active ingredients consisting of alfuzosine and apomorphine, and pharmaceutical compositions containing them, for ameliorating and/or treating erectile dysfunction in male patients.
    Type: Application
    Filed: July 17, 2003
    Publication date: April 1, 2004
    Inventors: Sonia Arbilla, Juan Fernando Ramirez
  • Publication number: 20040063737
    Abstract: This invention relates to 2-heteroaryl-pyrimidine derivatives of general formula I as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.
    Type: Application
    Filed: October 27, 2003
    Publication date: April 1, 2004
    Applicant: Schering AG
    Inventors: Ulrich Lucking, Martin Kruger, Rolf Jautelat, Olaf Prien, Gerhard Siemeister, Alexander Ernst
  • Publication number: 20040063738
    Abstract: Compounds of (I), and their N-oxides and agriculturally suitable salts, are disclosed which are useful for controlling invertebrate pests (Formula) wherein J is selected from the group consisting of J-1, J-2, J-3, J-4, J-5, J-6, J-7 and J-8 (I) and R1, R2, R3, R4, R5, R7, R9 and n are as defined in the disclosure. Also disclosed are compositions for controlling an invertebrate pest comprising a biologically effective amount of a compound of (I) and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of (I) (e.g., as a composition described herein).
    Type: Application
    Filed: April 30, 2003
    Publication date: April 1, 2004
    Inventors: George Philip Lahm, Thomas Paul Selby
  • Publication number: 20040063739
    Abstract: The present invention pertains to certain N8,N13-disubstituted quino[4,3,2-kl]acridinium salts of formula (Q−) which inhibit telomerase wherein: p is an integer from 0 to 4; q is an integer from 0 to 3; r is an integer from 0 to 4; each RA is —H or a ring substituent; each RB is —H or a ring substituent; each RC is —H or a ring substituent; RN8 is a nitrogen substituent; RN13 is a nitrogen substituent; and, Q is an anion. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative conditions, such as cancer.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 1, 2004
    Inventors: Malcolm F. G. Stevens, Lloyd R. Kelland, Robert A. Heald